Mallinckrodt to pay up to $47.5 mil. in expanded pact with Molecular Biosystems.
This article was originally published in The Gray Sheet
MALLINCKRODT INVESTING UP TO $47.5 MIL. IN MOLECULAR BIOSYSTEMS to support commercialization of FS069, a next generation version of MBI's Albunex ultrasound contrast imaging agent. Under the agreement, announced Sept. 7, Mallinckrodt will buy $13 mil. of MBI stock for $11.62 per share, raising its stake in the company to 10%. Mallinckrodt also will provide $20 mil. over four years to fund FS069 clinical trials and "associated product development." An additional $14.5 mil. for milestone payments and "further clinical funding" could bring the total value of the deal to $47.5 mil.
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.